Quidel Corporation (NASDAQ: QDEL) and Oxford Immunotec Global PLC (NASDAQ:OXFD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitabiliy, earnings, analyst recommendations and risk.
Valuation and Earnings
This table compares Quidel Corporation and Oxford Immunotec Global PLC’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Quidel Corporation||$214.97 million||4.01||$39.80 million||$0.10||259.83|
|Oxford Immunotec Global PLC||$90.47 million||3.81||-$22.95 million||($1.05)||-14.33|
Quidel Corporation has higher revenue and earnings than Oxford Immunotec Global PLC. Oxford Immunotec Global PLC is trading at a lower price-to-earnings ratio than Quidel Corporation, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations for Quidel Corporation and Oxford Immunotec Global PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global PLC||0||0||2||0||3.00|
Quidel Corporation presently has a consensus target price of $24.67, indicating a potential downside of 5.06%. Oxford Immunotec Global PLC has a consensus target price of $19.00, indicating a potential upside of 26.25%. Given Oxford Immunotec Global PLC’s stronger consensus rating and higher probable upside, analysts plainly believe Oxford Immunotec Global PLC is more favorable than Quidel Corporation.
Volatility and Risk
Quidel Corporation has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Oxford Immunotec Global PLC has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500.
This table compares Quidel Corporation and Oxford Immunotec Global PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global PLC||-25.83%||-31.48%||-22.01%|
Insider & Institutional Ownership
89.2% of Quidel Corporation shares are owned by institutional investors. Comparatively, 87.5% of Oxford Immunotec Global PLC shares are owned by institutional investors. 22.0% of Quidel Corporation shares are owned by insiders. Comparatively, 7.6% of Oxford Immunotec Global PLC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Quidel Corporation beats Oxford Immunotec Global PLC on 10 of the 13 factors compared between the two stocks.
Quidel Corporation Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.